IFNB1 and relapsing-remitting multiple sclerosis: In addition, accumulating evidence pointed towards significant improvements in disability status and MRI (magnetic resonance imaging) lesions in patients with relapsing-remitting MS who failed to respond to treatment with interferon beta [16–18].